Complement factor B
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Complement factor B as ChEMBL target CHEMBL4630808, mapped to UniProt P04186. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Complement factor B matters
Complement factor B is reviewed as Complement factor B (UniProt P04186); the current evidence base includes 1 approved drug, 7 compounds, and 1 assay, with lead potency reaching pChEMBL 7.1.
Complement factor B Sequence length is 761 aa.
Review this target as Complement factor B, mapped to UniProt P04186. Sequence length is 761 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 1 approved drug, 7 compounds, and 1 assay for this target. The dominant activity type is IC50. CHEMBL4639592 is the current potency anchor at pChEMBL 7.1.
Use CHEMBL4639592 as the tractability anchor when discussing potency (pChEMBL 7.1).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Complement factor B matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P04186, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4639592
|
7.1 | IC50 | — |
|
|
No preferred name
CHEMBL4594448
|
7.0 | IC50 | Approved |
|
|
No preferred name
CHEMBL4641109
|
6.9 | IC50 | — |
|
|
No preferred name
CHEMBL4644208
|
6.9 | IC50 | — |
|
|
No preferred name
CHEMBL4632794
|
6.8 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
IPTACOPAN
CHEMBL4594448
|
2023 |